Zymedi Co. Ltd. has signed a clinical cooperative research and development agreement (CRADA) with the National Heart, Lung and Blood Institute (NHLBI), part of the National Institutes of Health (NIH), to develop ZMA-001 for the treatment of pulmonary arterial hypertension (PAH).

Domain Therapeutics SA has nominated a novel drug candidate, DT-7012, an anti-CCR8 monoclonal antibody depleting tumor-infiltrating regulatory T cells (Tregs).

Iaso Biotechnology Co. Ltd. has received FDA approval of the company’s IND application for IASO-782 injection for use in U.S. clinical trials for autoimmune hematological disorders, including primary immune thrombocytopenia (ITP) and warm autoimmune hemolytic anemia (AIHA).

Alentis Therapeutics AG has received FDA clearance of the company’s IND application for ALE.C04, a first-in-class monoclonal antibody developed to specifically target exposed Claudin-1 (CLDN1) on cancer cells.

Cancervax Inc. has announced further progress made by its research team at the University of California, Los Angeles (UCLA) toward...

Aegis Life Inc. and its parent company Entos Pharmaceuticals Inc. (Entos) have entered into a grant agreement with the Bill & Melinda Gates Foundation in the area of infectious disease.

Scientists from the Hospital for Sick Children Research Institute and collaborators have reported the application of a multispecific, multiaffinity antibody (Multabody, MB) platform derived from the human apoferritin protomer to enable the multimerization of antibody fragments against SARS-CoV-2. These MBs showed high potency to neutralize SARS-CoV-2 even at lower concentrations than their corresponding MAb counterparts.

Laekna Therapeutics Shanghai Co. Ltd. has received FDA clearance of its IND application to initiate clinical development with LAE-102 in the U.S.

Antengene Corp. Ltd. has received FDA clearance of its IND for a phase I study of the first-in-class...